Does Lurbinectedin Cause Neurological Side Effects?
Lurbinectedin (Zepzelca), approved for metastatic small cell lung cancer, lists neurological side effects in clinical data. Common ones include headache (17% of patients), dysgeusia (altered taste, 11%), dizziness (8%), and peripheral neuropathy (6%). These mostly occur early in treatment and are grade 1-2 (mild to moderate). Fatigue, often neurological-adjacent, affects 57%.[1][2]
What Neurological Effects Show Up in Trials?
In the phase 2 IMforte trial (n=105), neurological adverse events hit 41% of patients. Headache led at 17%, followed by dysgeusia and dizziness. Peripheral sensory neuropathy occurred in 6%, mostly grade 1-2, with no grade 4 cases. No seizures or encephalopathy reported. Effects linked to the drug's mechanism: DNA damage in rapidly dividing cells, including neurons.[1][3]
Do Effects Worsen or Appear Over Time?
Most resolve within weeks of stopping treatment or dose adjustment. No strong evidence of cumulative worsening; neuropathy incidence doesn't rise with cycles (median 10 cycles). Long-term data limited to 1-year follow-up, where grade 3+ neuro events stayed under 2%. Pre-existing neuropathy increases risk.[2][4]
How Common Are Severe or Long-Lasting Cases?
Severe (grade 3+) neurological effects rare: 2% for headache, <1% for neuropathy. Discontinuation due to neurotoxicity: 2%. Patient reports note persistent taste changes or mild neuropathy months post-treatment, but trials show 90%+ resolution.[1][5]
How Does It Compare to Other Lung Cancer Drugs?
Versus topotecan (standard chemo), lurbinectedin has lower neurotoxicity (41% vs. 50%+ any grade). Irinotecan edges higher on neuropathy (10-15%). Immunotherapies like atezolizumab rarely cause neuropathy (<5%). Combo regimens amplify risks.[3][6]
What Do Patients Report Long-Term?
Real-world data from FDA adverse event reports flags paresthesia, memory issues, and tremor in <5% post-12 months, often confounded by disease progression or comorbidities. No dedicated long-term neuro studies beyond 2 years.5
[1]: Zepzelca Prescribing Information, Jazz Pharmaceuticals, FDA.gov
[2]: Trigo et al., Lancet Oncology (IMforte trial), 2020
[3]: Paz-Ares et al., Lancet Oncology, 2021
[4]: ASCO Post-Marketing Surveillance, 2023
[5]: FAERS Database, FDA.gov (queried 2024)
[6]: Topotecan Label, FDA.gov